By: Mamta Mayani, SA News Editor
Participants will receive paclitaxel, pelareorep in combination with paclitaxel alone, or pelareorep in combination with paclitaxel and Merck and Pfizer’s anti-PD-L1 checkpoint inhibitor, avelumab (Bavencio). The BRACELET-1 study will enroll 45 patients randomized into three cohorts.
The primary endpoint is overall response rate. Exploratory endpoints include peripheral and tumor T cell clonality, inflammatory markers, and safety and tolerability assessments.
ONCY is up 4% premarket.
Barbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide.